H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Gain Therapeutics to $8 from $9 and keeps a Buy rating on the shares. The analyst cites dilution from the company’s most recent share offering for the target drop.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GANX:
- Gain Therapeutics Leadership Changes and Executive Compensation
- Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
- Gain Therapeutics CEO Matthias Alder departs, Gene Mack named interim CEO
- Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
- Gain Therapeutics announces presentation of poster at FENS forum 2024